NewLimit, a 1.5-year-old, San Francisco-based, 17-person company that aims to increase the number of healthy years each person lives by epigenetically reprogramming cells, is today announcing that it has raised $40 million in Series A funding from Dimension, Kleiner Perkins, Founders Fund, and other investors to further its mission to extend humans’ health and lives.
We talked with two of the companies’ four cofounders yesterday, including Coinbase CEO Brian Armstrong and VC Blake Byers, who has a Stanford PhD in bioengineering. During that chat, we got more insight into the round,
コメント